Luspatercept in β-thalassemia: Who and when. Strengths and weaknesses points of a real-world evidence
EJHaem
.
2024 Nov 4;5(6):1354-1358.
doi: 10.1002/jha2.1032.
eCollection 2024 Dec.
Authors
Lorenza Torti
1
,
Nicolina Ardu
1
,
Laura Maffei
1
,
Paolo De Fabritiis
1
,
Francesco Sorrentino
1
Affiliation
1
Hemoglobinopathies Unit, Hematology Department, S. Eugenio Hospital (ASL Roma 2) Regional Center for the Diagnosis and Treatment of Rare Anemias and Disorders of Iron Metabolism Rome Italy.
PMID:
39691262
PMCID:
PMC11647712
DOI:
10.1002/jha2.1032
No abstract available
Keywords:
adverse events; luspatercept; thalassemia; thrombocytosis; transfusional therapy.